SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
In a photo illustration, prescription drugs are seen in pill bottles on July 23, 2024 in New York City.
(Photo: Spencer Platt/Getty Images)
Trump Rescinds Biden Order Aimed at Lowering Prescription Drug Prices
"Trump is again proving that he lied to the American people and doesn't care about lowering costs—only what's best for himself and his ultra-rich friends."
Jan 21, 2025
As part of a flurry of executive actions on the first day of his second White House term, President Donald Trump on Monday rescinded an order signed by his predecessor that aimed to develop programs to lower prescription drug prices in the United States—where residents pay far more for medications than people in peer countries.
News of Trump's rollback of Executive Order 14087—titled Lowering Prescription Drug Costs for Americans—was buried amid dozens of other rescissions the president ordered shortly following his inauguration.
The decision to scrap Executive Order 14087 brings to a halt several pilot programs undertaken by the Center for Medicare and Medicaid Innovation, including an experiment that involved offering generic medications for a $2 copay to Medicare Part D recipients.
"This act is a good indication of how Trump will approach lower drug prices," Social Security Works, a progressive advocacy group, wrote in response to Trump's rescission of President Joe Biden's executive order.
Larry Levitt, executive vice president for health policy at KFF, added that "the big question, which Trump hasn't addressed yet, is what he’ll do with government negotiation of drug prices under the Inflation Reduction Act."
Just days before Trump took office, the Biden administration announced a fresh slate of 15 medications set to be subject to direct price negotiations between the federal government and pharmaceutical companies, many of which have sued over the negotiation program—thus far unsuccessfully.
Reuters reported last week that the powerful pharmaceutical lobby has been pushing Trump's team to back changes to the Inflation Reduction Act that would weaken the price-negotiation provisions.
"Donald Trump is already following through on his dangerous plans to jack up the costs of drugs to appease his billionaire backers after the Biden-Haris administration took on Big Pharma and won," Alex Floyd, rapid response director for the Democratic National Committee, said in a statement. "Trump is again proving that he lied to the American people and doesn't care about lowering costs—only what's best for himself and his ultra-rich friends."
Responding more broadly to the president's day-one wave of unilateral actions—which included attacks on immigrants and the climate—Working Families Party national director Maurice Mitchell said Tuesday that "Trump's flood of executive orders is just a cheap spectacle meant to distract us while his administration moves to gut our healthcare and SNAP benefits."
"Immigrant families aren't the reason we can't afford eggs or prescription drugs; billionaire CEOs are," Mitchell added.
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, The U.S. is on a fast track to authoritarianism like nothing I've ever seen. Meanwhile, corporate news outlets are utterly capitulating to Trump, twisting their coverage to avoid drawing his ire while lining up to stuff cash in his pockets. That's why I believe that Common Dreams is doing the best and most consequential reporting that we've ever done. Our small but mighty team is a progressive reporting powerhouse, covering the news every day that the corporate media never will. Our mission has always been simple: To inform. To inspire. And to ignite change for the common good. Now here's the key piece that I want all our readers to understand: None of this would be possible without your financial support. That's not just some fundraising cliche. It's the absolute and literal truth. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. Will you donate now to help power the nonprofit, independent reporting of Common Dreams? Thank you for being a vital member of our community. Together, we can keep independent journalism alive when it’s needed most. - Craig Brown, Co-founder |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
As part of a flurry of executive actions on the first day of his second White House term, President Donald Trump on Monday rescinded an order signed by his predecessor that aimed to develop programs to lower prescription drug prices in the United States—where residents pay far more for medications than people in peer countries.
News of Trump's rollback of Executive Order 14087—titled Lowering Prescription Drug Costs for Americans—was buried amid dozens of other rescissions the president ordered shortly following his inauguration.
The decision to scrap Executive Order 14087 brings to a halt several pilot programs undertaken by the Center for Medicare and Medicaid Innovation, including an experiment that involved offering generic medications for a $2 copay to Medicare Part D recipients.
"This act is a good indication of how Trump will approach lower drug prices," Social Security Works, a progressive advocacy group, wrote in response to Trump's rescission of President Joe Biden's executive order.
Larry Levitt, executive vice president for health policy at KFF, added that "the big question, which Trump hasn't addressed yet, is what he’ll do with government negotiation of drug prices under the Inflation Reduction Act."
Just days before Trump took office, the Biden administration announced a fresh slate of 15 medications set to be subject to direct price negotiations between the federal government and pharmaceutical companies, many of which have sued over the negotiation program—thus far unsuccessfully.
Reuters reported last week that the powerful pharmaceutical lobby has been pushing Trump's team to back changes to the Inflation Reduction Act that would weaken the price-negotiation provisions.
"Donald Trump is already following through on his dangerous plans to jack up the costs of drugs to appease his billionaire backers after the Biden-Haris administration took on Big Pharma and won," Alex Floyd, rapid response director for the Democratic National Committee, said in a statement. "Trump is again proving that he lied to the American people and doesn't care about lowering costs—only what's best for himself and his ultra-rich friends."
Responding more broadly to the president's day-one wave of unilateral actions—which included attacks on immigrants and the climate—Working Families Party national director Maurice Mitchell said Tuesday that "Trump's flood of executive orders is just a cheap spectacle meant to distract us while his administration moves to gut our healthcare and SNAP benefits."
"Immigrant families aren't the reason we can't afford eggs or prescription drugs; billionaire CEOs are," Mitchell added.
As part of a flurry of executive actions on the first day of his second White House term, President Donald Trump on Monday rescinded an order signed by his predecessor that aimed to develop programs to lower prescription drug prices in the United States—where residents pay far more for medications than people in peer countries.
News of Trump's rollback of Executive Order 14087—titled Lowering Prescription Drug Costs for Americans—was buried amid dozens of other rescissions the president ordered shortly following his inauguration.
The decision to scrap Executive Order 14087 brings to a halt several pilot programs undertaken by the Center for Medicare and Medicaid Innovation, including an experiment that involved offering generic medications for a $2 copay to Medicare Part D recipients.
"This act is a good indication of how Trump will approach lower drug prices," Social Security Works, a progressive advocacy group, wrote in response to Trump's rescission of President Joe Biden's executive order.
Larry Levitt, executive vice president for health policy at KFF, added that "the big question, which Trump hasn't addressed yet, is what he’ll do with government negotiation of drug prices under the Inflation Reduction Act."
Just days before Trump took office, the Biden administration announced a fresh slate of 15 medications set to be subject to direct price negotiations between the federal government and pharmaceutical companies, many of which have sued over the negotiation program—thus far unsuccessfully.
Reuters reported last week that the powerful pharmaceutical lobby has been pushing Trump's team to back changes to the Inflation Reduction Act that would weaken the price-negotiation provisions.
"Donald Trump is already following through on his dangerous plans to jack up the costs of drugs to appease his billionaire backers after the Biden-Haris administration took on Big Pharma and won," Alex Floyd, rapid response director for the Democratic National Committee, said in a statement. "Trump is again proving that he lied to the American people and doesn't care about lowering costs—only what's best for himself and his ultra-rich friends."
Responding more broadly to the president's day-one wave of unilateral actions—which included attacks on immigrants and the climate—Working Families Party national director Maurice Mitchell said Tuesday that "Trump's flood of executive orders is just a cheap spectacle meant to distract us while his administration moves to gut our healthcare and SNAP benefits."
"Immigrant families aren't the reason we can't afford eggs or prescription drugs; billionaire CEOs are," Mitchell added.
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.